Vaxcyte/$PCVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vaxcyte
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Ticker
$PCVX
Sector
Primary listing
Employees
507
Headquarters
Website
Vaxcyte Metrics
BasicAdvanced
$6.8bn
-
-$6.91
1.30
-
Price and volume
Market cap
$6.8bn
Beta
1.3
52-week high
$65.00
52-week low
$29.08
Average daily volume
1.5m
Financial strength
Current ratio
7.491
Quick ratio
7.176
Long term debt to equity
3.679
Total debt to equity
3.882
Profitability
EBITDA (TTM)
-1,072.345
Management effectiveness
Return on assets (TTM)
-20.23%
Return on equity (TTM)
-30.55%
Valuation
Price to book
2.28
Price to tangible book (TTM)
2.28
Price to free cash flow (TTM)
-7.954
Free cash flow yield (TTM)
-12.57%
Free cash flow per share (TTM)
-5.947
Growth
Earnings per share change (TTM)
73.47%
3-year earnings per share growth (CAGR)
26.65%
What the Analysts think about Vaxcyte
Analyst ratings (Buy, Hold, Sell) for Vaxcyte stock.
Vaxcyte Financial Performance
Revenues and expenses
Vaxcyte Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs